Display options
Cite
Martinello M, Dore GJ, Skurowski J, et al. Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. Open Forum Infect Dis. 2016;3(2):ofw105doi: 10.1093/ofid/ofw105.
Martinello, M., Dore, G. J., Skurowski, J., Bopage, R. I., Finlayson, R., Baker, D., Bloch, M., & Matthews, G. V. (2016). Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. Open forum infectious diseases, 3(2), ofw105. https://doi.org/10.1093/ofid/ofw105
Martinello, Marianne, et al. "Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection." Open forum infectious diseases vol. 3,2 (2016): ofw105. doi: https://doi.org/10.1093/ofid/ofw105
Martinello M, Dore GJ, Skurowski J, Bopage RI, Finlayson R, Baker D, Bloch M, Matthews GV. Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. Open Forum Infect Dis. 2016 May 18;3(2):ofw105. doi: 10.1093/ofid/ofw105. eCollection 2016 Apr. PMID: 27419177; PMCID: PMC4943543.
Copy Download .nbib Format: NLM
Share it on

Open Forum Infect Dis. 2016 May 18;3(2):ofw105. doi: 10.1093/ofid/ofw105. eCollection 2016 Apr.

Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection.

Open forum infectious diseases

Marianne Martinello, Gregory J Dore, Jasmine Skurowski, Rohan I Bopage, Robert Finlayson, David Baker, Mark Bloch, Gail V Matthews

Affiliations

  1. Viral Hepatitis Clinical Research Program, The Kirby Institute, University of New South Wales (UNSW) Australia, Sydney; Department of Infectious Diseases and Immunology, St Vincent's Hospital, Sydney, New South Wales.
  2. Viral Hepatitis Clinical Research Program , The Kirby Institute, University of New South Wales (UNSW) Australia , Sydney.
  3. The Albion Centre, Sydney, New South Wales; School of Public Health and Community Medicine, UNSW Australia, Sydney, New South Wales.
  4. Taylor Square Private Clinic , Sydney, New South Wales.
  5. East Sydney Doctors , New South Wales.
  6. Holdsworth House Medical Practice , Sydney, New South Wales , Australia.

PMID: 27419177 PMCID: PMC4943543 DOI: 10.1093/ofid/ofw105

Abstract

Background.  Interferon-free direct-acting antiviral (DAA) regimens for hepatitis C virus (HCV) provide a major advance in clinical management, including in human immunodeficiency virus (HIV)/HCV coinfection. Drug-drug interactions (DDIs) with combination antiretroviral therapy (cART) require consideration. This study aimed to characterize the cART regimens in HIV/HCV-coinfected individuals and assess the clinical significance of DDIs with DAAs in a real-world cohort. Methods.  This analysis included participants enrolled in CEASE-D, a prospective cohort of HIV/HCV-coinfected individuals in Sydney, Australia, between July 2014 and December 2015. A simulation of potential DDIs between participants' cART and interferon-free DAA regimens was performed using www.hep-druginteractions.org and relevant prescribing information. Results.  In individuals on cART with HCV genotype (GT) 1 and 4 (n = 128), category 3 DDIs (contraindicated or not recommended) were noted in 0% with sofosbuvir/ledipasvir, 0% with sofosbuvir plus daclatasvir, 17% with sofosbuvir/velpatasvir, 36% with ombitasvir/paritaprevir/ritonavir ± dasabuvir, 51% with grazoprevir/elbasvir, and 51% with sofosbuvir plus simeprevir; current cART regimens were suitable for coadministration in 100%, 100%, 73%, 64%, 49%, and 49%, respectively. In individuals with HCV GT 2 or 3 (n = 53), category 3 DDIs were evident in 0% with sofosbuvir plus daclatasvir, 0% with sofosbuvir and ribavirin, and 13% with sofosbuvir/velpatasvir; current cART regimens were suitable in 100%, 100%, and 81%, respectively. Conclusions.  Potential DDIs are expected and will impact on DAA prescribing in HIV/HCV coinfection. Sofosbuvir in combination with an NS5A inhibitor or ribavirin appeared to be the most suitable regimens in this cohort. Evaluation of potential DDIs is required to prevent adverse events or treatment failure.

Keywords: HIV; antiretroviral therapy; direct-acting antiviral therapy; drug-drug interactions; hepatitis C

References

  1. Hepatology. 2005 Jan;41(1):48-54 - PubMed
  2. Hepatology. 2005 Apr;41(4):779-89 - PubMed
  3. J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):175-9 - PubMed
  4. Hepatology. 2009 Jan;49(1):22-31 - PubMed
  5. Hepatology. 2009 Apr;49(4):1335-74 - PubMed
  6. Clin Infect Dis. 2012 Jul;55(1):137-44 - PubMed
  7. Clin Infect Dis. 2012 Sep;55(5):728-36 - PubMed
  8. J Hepatol. 2012 Oct;57(4):743-51 - PubMed
  9. Curr Opin Infect Dis. 2013 Feb;26(1):50-7 - PubMed
  10. J Hepatol. 2014 Nov;61(1 Suppl):S45-57 - PubMed
  11. J Int AIDS Soc. 2014 Nov 02;17(4 Suppl 3):19626 - PubMed
  12. Lancet. 2015 Jan 10;385(9963):117-71 - PubMed
  13. Lancet. 2015 Mar 21;385(9973):1098-106 - PubMed
  14. JAMA. 2015 Mar 24-31;313(12):1223-31 - PubMed
  15. JAMA. 2015 Mar 24-31;313(12):1232-9 - PubMed
  16. Clin Infect Dis. 2015 Jun 15;60(12):1829-36 - PubMed
  17. J Hepatol. 2015 Jul;63(1):199-236 - PubMed
  18. AIDS Patient Care STDS. 2015 Jul;29(7):379-83 - PubMed
  19. N Engl J Med. 2015 Aug 20;373(8):714-25 - PubMed
  20. N Engl J Med. 2015 Aug 20;373(8):705-13 - PubMed
  21. Lancet HIV. 2015 Aug;2(8):e319-27 - PubMed
  22. PLoS One. 2015 Oct 21;10(10):e0141164 - PubMed
  23. Clin Infect Dis. 2016 Mar 1;62(5):561-7 - PubMed
  24. Clin Infect Dis. 2016 Apr 15;62(8):972-9 - PubMed
  25. Lancet Infect Dis. 2016 Jul;16(7):797-808 - PubMed
  26. Gastroenterol Hepatol (N Y). 2016 Jun;12(6 Suppl 2):1-22 - PubMed

Publication Types